Pharma’s Patent Cliff, Reconsidered
The cliff is real, but so is the playbook — and the capital moving around it.
Between 2025 and 2030, the pharmaceutical industry faces the expiration of patents covering drugs generating an estimated $300 billion in annual revenue. The names are familiar: Eliquis, Keytruda, Humira’s siblings. What is less discussed is how systematically the major houses have been repositioning capital ahead of the drop, and what that repositioning reveals about where durable value is being constructed.
The Structure of the Problem
Patent cliffs are not surprises. They are scheduled events, visible years in advance on any pipeline calendar. What makes the current cycle notable is the concentration: several of the largest revenue-generating drugs in history are losing exclusivity within the same five-year window. Merck’s Keytruda alone accounts for roughly $25 billion in annual revenue, with its primary composition-of-matter patent expiring in 2028 in key markets.
The displacement from generics and biosimilars is not uniform. Small-molecule drugs typically face price erosion of 80 to 90 percent within two years of generic entry. Biologics, by contrast, see slower biosimilar penetration due to manufacturing complexity and physician inertia, often retaining 40 to 60 percent of volume several years post-expiration. That distinction is shaping where defense capital is being allocated.
Where the Capital Is Going
The observable pattern across AstraZeneca, Pfizer, Novo Nordisk, and others is a dual-track response: aggressive pipeline M&A to replace revenue, and operational repositioning toward high-barrier therapeutic areas. AstraZeneca’s acquisitions of Alexion and Rare Disease Genetics assets reflect a deliberate move toward orphan drug designations, which carry longer effective exclusivity periods and compressed biosimilar competition. Pfizer’s post-Paxlovid capital deployment into oncology and hematology follows similar logic.
GLP-1 receptor agonists represent the other concentration point. Novo Nordisk and Eli Lilly are effectively insulated from near-term cliff concerns by demand dynamics in obesity and diabetes that are structurally outpacing supply. Capital markets have priced this, but operators are watching the manufacturing capacity constraints, particularly fill-and-finish bottlenecks, as the binding variable in near-term revenue realization.
- Orphan and rare disease assets: Extended exclusivity windows, limited generic competition, and pricing power that generic entry rarely erodes.
- Oncology combinations and biomarker-defined indications: Narrower populations, but defensible formulary positioning and label expansion optionality.
- Radiopharmaceuticals: An emerging structural bet. Eli Lilly’s acquisition of Point Biopharma and Bristol Myers Squibb’s RayzeBio deal signal capital conviction in a manufacturing-differentiated modality.
The Licensing and Royalty Layer
Less visible but structurally important is the activity in royalty monetization. Royalty Pharma and similar vehicles have seen increased deal flow as large pharma looks to accelerate cash against future royalty streams, freeing balance sheet capacity for pipeline replenishment. This creates observable secondary market dynamics where the royalty asset class absorbs risk that originator companies prefer to sell. For capital allocators watching the pharmaceutical ecosystem, the royalty layer often reflects pipeline confidence signals that precede public pipeline disclosures.
Licensing-in activity from mid-cap and large-cap pharma targeting late-stage Phase 2 and Phase 3 assets has also accelerated, particularly in CNS, immunology, and oncology. Smaller biotech is functioning increasingly as a distributed R&D arm, with major pharma providing the commercial infrastructure at the point of validated clinical proof.
The Operator Read
The cliff creates pressure, but pressure is a known input here, not a revelation. The structural question is which companies have used the lead time to build defensible replacement revenue versus which have relied on share buybacks and dividend maintenance while pipeline gaps widen. The capital flows into rare disease, radiopharmaceuticals, and royalty vehicles suggest where sophisticated allocators are placing durability bets. The manufacturing constraint story in GLP-1s, meanwhile, is worth tracking independently of the patent cliff narrative entirely.
The conversations that move outcomes happen in private rooms.
The Marczell Klein Platinum Partnership is a high-proximity ecosystem for operators, investors, and entrepreneurs. By application only.
Apply for Platinum Access →Editorial & market-views disclosure. This article expresses general market views, observations, and educational commentary. It is not financial, investment, legal, tax, or accounting advice; not a recommendation to buy, sell, hold, or otherwise transact in any security, asset, or instrument; and not personalized to any reader’s circumstances. Markets are uncertain and capital can be lost in part or in whole.
No advisory relationship. Neither Marczell Klein nor Marczell Klein Corp acts as a broker-dealer, registered investment adviser, municipal advisor, commodity trading advisor, crowdfunding portal, fiduciary, or placement agent through this content. No advisory relationship is created by reading or relying on anything here.
Do your own work. Consult your own licensed counsel, tax advisors, accountants, registered investment advisers, and other qualified professionals before acting on any information. Past performance does not predict future results. Forward-looking statements and projections are inherently uncertain.
Material connections. The author and/or affiliated entities may hold positions in, transact in, or have material relationships with assets, sectors, or companies discussed. Specific holdings are not disclosed.
Securities & offerings. Nothing in this article constitutes an offer to sell, solicitation of an offer to buy, or recommendation regarding any security or interest in any fund, vehicle, or program. Any securities offering, if ever made, would be made only through definitive offering documents and only to eligible persons under applicable law.
© 2026 Marczell Klein Corp, a State of California S-Corporation.